21 - "Value-based public procurement of innovation: an instrument to foster in silico medicine adoption into clinical practice"
Host: Rossana Alessandrello, PhD
MSc in Electronic Engineering from the Politecnico di Milano
Value Based Procurement Director at AQuAS
ABSTRACT: It is not enough for the innovative technologies, including CM&S, to comply with all the relevant regulatory requirements to be than adopted and deployed across the health systems. Adoption is possible when the healthcare providers and the health systems can afford its deployment at all the levels. Deciding whether investing in in silico research and developments (pre-commercial procurements) and/or in innovative in silico technologies (public procurement of innovations) require a clear understanding of what unmet needs the novel CM&S technologies are addressing and what potential impact is generated by addressing such needs. Value based risk & benefit sharing contracts can be of support to align industry efforts and health care procurers needs.
BIO: Rossana Alessandrello is Value Based Procurement Director at AQuAS, MSc in Electronic Engineering from the Politecnico di Milano, she is specialized in Bioengineering and certified in BA from the Manchester Business School. In her role, she supports the healthcare providers of the Catalan health system in identifying their unmet needs, in assessing the business cases supporting the relevant investments and in designing crossborder value based risks sharing public procurement tenders (pre commercial, PCP, or of innovation, PPI). She makes part of the academic team of iRaise Education Programme (https://www.iraise.eu/ ) coordinated by Universitat Politecnica de Valencia, the Big Buyers Digital solutions in the healthcare sector working group and the team who evaluates the proposal submitted to the Open Call for Innovation and the Impact programme from CIMTI (Centre per a la Integració de la Medicina i les Tecnologies Innovadores). She is a member of VPH Institute Board of Directors and In Silico World Advisory Board.
